{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:45:17Z","timestamp":1792395917767,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004358","name":"Samsung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004358","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Phase III clinical trials of the tumour necrosis factor inhibitors SB4, SB2, and SB5 (biosimilars to etanercept, infliximab, and adalimumab, respectively) have demonstrated efficacy in moderate-to-severe rheumatoid arthritis (RA). Data from these trials were used to identify baseline characteristics associated with radiographic progression and to build a matrix risk model for its prediction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with radiographic progression and baseline demographic and disease characteristic data were pooled across the 3 phase III studies of each biosimilar and its reference product. Baseline demographics and disease characteristics were evaluated for their relationship with radiographic progression (1-year mean change in mTSS &gt;\u20090); 3 factors were selected based on strongest Pearson\u2019s correlation coefficient with the change in modified Total Sharp Score. Univariate logistic regression was performed to assess the association between each baseline factor and the rate of radiographic progression, with subsequent matrix model development performed using multivariate logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1371 patients were included in the analysis, with a radiographic progression rate of 27.4%. The 3 baseline predictors of radiographic progression, based on Pearson\u2019s correlation coefficient, were 28 swollen joint count (SJC28), C-reactive protein (CRP), and physician global assessment (PhGA). A matrix model showed that the predicted risk of radiographic progression was higher with the increased level of SJC28, CRP, and PhGA (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this pooled analysis of phase III clinical trial data of biosimilars for RA, identifiable baseline factors (SJC28, CRP, and PhGA) associated with radiographic progression were similar to those described in prior studies. Even though radiographic progression was minimal, a small number of patients who have increased SJC28, CRP, and PhGA at baseline should be closely monitored and follow treat-to-target approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration numbers<\/jats:title>\n                <jats:p>EudraCT 2012-005026-30. Registered 30 April 2013, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005026-30\/results\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005026-30\/results<\/jats:ext-link><\/jats:p>\n                <jats:p>EudraCT 2012-005733-37. Registered 10 July 2013, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005733-37\/results\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-005733-37\/results<\/jats:ext-link><\/jats:p>\n                <jats:p>EudraCT 2013-005013-13. Registered 01 April 2014, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-005013-13\/results\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-005013-13\/results<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02267-z","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T13:03:00Z","timestamp":1597410180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Mo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hee","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Keystone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gihyun","family":"Myung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inyoung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehoon","family":"Ghil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"issue":"1","key":"2267_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1185\/03007990903422307","volume":"26","author":"H Birnbaum","year":"2010","unstructured":"Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26(1):77\u201390.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2267_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2267_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123\u201330.","journal-title":"Semin Arthritis Rheum"},{"key":"2267_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12891-015-0562-x","volume":"16","author":"M van Vilsteren","year":"2015","unstructured":"van Vilsteren M, Boot CR, Knol DL, van Schaardenburg D, Voskuyl AE, Steenbeek R, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015;16:107.","journal-title":"BMC Musculoskelet Disord"},{"issue":"13","key":"2267_CR5","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360\u201372.","journal-title":"JAMA."},{"issue":"1","key":"2267_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"2267_CR7","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"2267_CR8","volume-title":"Rheumatoid arthritis: national clinical guideline for management and treatment in adults","author":"The National Collaborating Centre for Chronic Conditions","year":"2018","unstructured":"The National Collaborating Centre for Chronic Conditions. Rheumatoid arthritis: national clinical guideline for management and treatment in adults. London: Royal College of Physicians; 2018."},{"issue":"9","key":"2267_CR9","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/art.22052","volume":"54","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2006;54(9):2784\u201392.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2267_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/ard.2009.114652","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis. 2010;69(6):1058\u201364.","journal-title":"Ann Rheum Dis"},{"key":"2267_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12864-016-2415-x","volume":"17","author":"S Royaert","year":"2016","unstructured":"Royaert S, Jansen J, da Silva DV, de Jesus Branco SM, Livingstone DS 3rd, Mustiga G, et al. Identification of candidate genes involved in Witches\u2019 broom disease resistance in a segregating mapping population of Theobroma cacao L. in Brazil. BMC Genomics. 2016;17:107.","journal-title":"BMC Genomics"},{"issue":"5 Suppl 101","key":"2267_CR12","first-page":"S40","volume":"34","author":"PL van Riel","year":"2016","unstructured":"van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S40\u2013s4.","journal-title":"Clin Exp Rheumatol"},{"key":"2267_CR13","volume-title":"Full prescribing information","author":"Remicade\u00ae (infliximab)","year":"2018","unstructured":"Remicade\u00ae (infliximab). Full prescribing information. Horsham: Janssen Biotech, Inc.; 2018."},{"issue":"3","key":"2267_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702\u201310.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2267_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/art.20982","volume":"52","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52(4):1020\u201330.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2267_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26\u201337.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2267_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/art.27268","volume":"62","author":"P Emery","year":"2010","unstructured":"Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum. 2010;62(3):674\u201382.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2267_CR18","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381\u201390.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2267_CR19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400\u201311.","journal-title":"Arthritis Rheum"},{"issue":"9194","key":"2267_CR20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (London). 1999;354(9194):1932\u20139.","journal-title":"Lancet (London)"},{"issue":"1","key":"2267_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27\u201335.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2267_CR22","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1002\/art.23141","volume":"56","author":"D van der Heijde","year":"2007","unstructured":"van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(12):3928\u201339.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2267_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35\u201345.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2267_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/art.21734","volume":"54","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(4):1075\u201386.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2267_CR25","first-page":"238","volume":"29","author":"L Klareskog","year":"2011","unstructured":"Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29(2):238\u201347.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"2267_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/ard.2005.044404","volume":"65","author":"ME Weinblatt","year":"2006","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006;65(6):753\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2267_CR27","doi-asserted-by":"publisher","first-page":"R249","DOI":"10.1186\/ar4092","volume":"14","author":"B Fautrel","year":"2012","unstructured":"Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther. 2012;14(6):R249.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2267_CR28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","volume":"48","author":"N Vastesaeger","year":"2009","unstructured":"Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1114\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2267_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/ard.2009.121160","volume":"69","author":"K Visser","year":"2010","unstructured":"Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010;69(7):1333\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2267_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/ard.51.2.177","volume":"51","author":"DM van der Heijde","year":"1992","unstructured":"van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis. 1992;51(2):177\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2267_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/annrheumdis-2012-201970","volume":"72","author":"D Aletaha","year":"2013","unstructured":"Aletaha D, Alasti F, Smolen JS. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. Ann Rheum Dis. 2013;72(1):7\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2267_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","volume":"71","author":"JS Smolen","year":"2012","unstructured":"Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2267_CR33","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/art.22143","volume":"54","author":"R Landewe","year":"2006","unstructured":"Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006;54(10):3119\u201325.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2267_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/ncprheum0050","volume":"1","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Aletaha D. Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1(2):62\u20133.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"6","key":"2267_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.2008.090019","volume":"68","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68(6):823\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2267_CR36","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3899\/jrheum.081018","volume":"36","author":"P Emery","year":"2009","unstructured":"Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009;36(7):1429\u201341.","journal-title":"J Rheumatol"},{"issue":"6","key":"2267_CR37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","volume":"74","author":"K Hambardzumyan","year":"2015","unstructured":"Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015;74(6):1102\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2267_CR38","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2010.146043","volume":"70","author":"MU Rahman","year":"2011","unstructured":"Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis. 2011;70(9):1631\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2267_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):51\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2267_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/annrheumdis-2015-207764","volume":"76","author":"JY Choe","year":"2017","unstructured":"Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76(1):58\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2267_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol (Hoboken). 2018;70(1):40\u20138.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"10","key":"2267_CR42","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/rheumatology\/kex254","volume":"56","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology (Oxford). 2017;56(10):1771\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2267_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol (Hoboken). 2018;70(6):832\u201340.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"12","key":"2267_CR44","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/rheumatology\/kex269","volume":"56","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2017;56(12):2093\u2013101.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2267_CR45","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000;27(1):261\u20133.","journal-title":"J Rheumatol"},{"issue":"3","key":"2267_CR46","first-page":"743","volume":"26","author":"D van der Heijde","year":"1999","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 1999;26(3):743\u20135.","journal-title":"J Rheumatol"},{"issue":"11","key":"2267_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","volume":"15","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol. 2019;15(11):633\u20134.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2267_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2267_CR49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3899\/jrheum.131468","volume":"41","author":"Y Kaneko","year":"2014","unstructured":"Kaneko Y, Kuwana M, Kondo H, Takeuchi T. Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment. J Rheumatol. 2014;41(6):1061\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"2267_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/acr.20685","volume":"64","author":"NA Khan","year":"2012","unstructured":"Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, et al. Determinants of discordance in patients\u2019 and physicians\u2019 rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012;64(2):206\u201314.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"2267_CR51","first-page":"540","volume":"25","author":"K Pavelka","year":"2007","unstructured":"Pavelka K, Gatterova J, Tegzova D, Jarosova K, Tomasova Studynkova J, Svobodnik A, et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. Clin Exp Rheumatol. 2007;25(4):540\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"2267_CR52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13075-015-0736-9","volume":"17","author":"D Aletaha","year":"2015","unstructured":"Aletaha D, Alasti F, Smolen JS. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:229.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2267_CR53","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/art.38307","volume":"66","author":"J Sokolove","year":"2014","unstructured":"Sokolove J, Johnson DS, Lahey LJ, Wagner CA, Cheng D, Thiele GM, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatology (Hoboken). 2014;66(4):813\u201321.","journal-title":"Arthritis Rheumatology (Hoboken)"},{"issue":"7","key":"2267_CR54","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1136\/annrheumdis-2013-204543","volume":"74","author":"L Laurent","year":"2015","unstructured":"Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, et al. IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann Rheum Dis. 2015;74(7):1425\u201331.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02267-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02267-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02267-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:22:01Z","timestamp":1650536521000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02267-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2267"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02267-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"7 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Three studies included were conducted in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines established by the International Conference Harmonisation. All subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Josef S. Smolen has received personal remuneration from AbbVie, Amgen, Astra-Zeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Novo-Nordisk, Pfizer, Roche, Samsung, Sanofi, and UCB and research funding from AbbVie, Janssen, Lilly, Novartis-Sandoz, Pfizer, and Roche. Michael E. Weinblatt has received research funding from Bristol-Myers Squibb, Crescendo Bioscience, and Sanofi\/Regeneron; has served as a consultant and\/or advisory board member for AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Corrona, GSK, Gilead, Lilly, Lycera, Merck, Novartis, Pfizer, Roche, Samsung Bioepis, and Set Point; and has financial interests\/stock ownership in Lycera, Canfite, Scipher, and Vorso. Paul Emery has been a clinical trials investigator and advisor to Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz, and Lilly and has received consulting fees from Bristol-Myers Squibb, AbbVie, Gilead, Pfizer, MSD, Novartis, Roche, and UCB; his employer has received research grants from AbbVie, Bristol-Myers Squibb, Pfizer, MSD, and Roche. Edward C. Keystone has received research funding from AbbVie, Amgen, Lilly, Gilead, Pfizer, PuraPharm, Sanofi, and Merck; has served as a consultant and\/or advisory board member for AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celltrion, Crescendo Bioscience, Roche, Genentech, Gilead, Janssen, Lilly, Merck, Pfizer, Sandoz, Sanofi, and Samsung Bioepis; and has received speaker honoraria for Amgen, AbbVie, Bristol-Myers Squibb, Roche, Janssen, Merck, Pfizer, Sanofi, and UCB. Mark C. Genovese has received research funding from AbbVie and has received consulting fees from Samsung Bioepis, Merck, Abbvie, Amgen, and FKB. Gihyun Myung, Inyoung Baek, and Jeehoon Ghil are employees of Samsung Bioepis. Jung-Yoon Choe has no financial disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}